Home / Market News / $GILD
fiscal.ai Corporate Catalyst Impact 92/100 ● neutral

Lazard Acts as Financial Advisor to Gilead Sciences in $1.275 Billion Acquisition of PepStar Program

Oct 23, 2026, 11:36 AM UTC · Primary ticker $GILD

Gilead Sciences is acquiring PepStar Therapeutics' investigational IL-23R inhibitor program for $1.275 billion, a significant M&A event in the biopharmaceutical sector. This acquisition could bolster Gilead's pipeline and future revenue streams, impacting its stock and potentially competitors in the immunology space.

Gilead Sciences announced a definitive agreement to acquire PepStar Therapeutics' IL-23R inhibitor program for $1.275 billion in upfront cash. This is a significant strategic move for Gilead, as it expands its pipeline with a potentially high-value asset in immunology, a key therapeutic area. The acquisition could lead to long-term revenue growth for Gilead if the drug successfully progresses through clinical trials and gains regulatory approval. For PepStar, this represents a substantial exit and validation of its research. Short-term, Gilead's stock might see a positive reaction due to the pipeline expansion, while long-term success hinges on the acquired program's clinical development. Traders should monitor Gilead's R&D updates and competitor reactions in the immunology market.

$GILD positive Acquiring new drug program
$PSTX positive Acquired for $1.275 billion
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.